Blinatumomab Extends Survival for Patients with Advanced ALL

Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.

Cancer Currents: An NCI Cancer Research Blog